GuidelineCurrent

CHEST VTE 2021 — Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report

American College of Chest Physicians, 2021

Evidence-based recommendations for initial treatment, treatment phase and extended-phase antithrombotic therapy in venous thromboembolism. Agent, intensity and duration should be selected according to VTE phenotype, bleeding risk, renal function, cancer/pregnancy status and procedural context rather than by a single ICU-wide regimen.

Strong recommendationModerate certainty

View source guideline

Clinical Context & Relevant Topics (2)

Disease Reference

Acute Pulmonary Embolism

Pulmonary vascular occlusion, acute RV pressure overload, ESC/AHA risk stratification, systemic thrombolysis, catheter-directed therapies, and hemodynamic support.

View Topic Context →

Therapeutic Anticoagulation & Emergency Reversal in the ICU

UFH vs LMWH vs DTIs (Argatroban/Bivalirudin), anti-Xa vs aPTT monitoring, and emergency reversal (Protamine, 4F-PCC, Idarucizumab; historical andexanet evidence with current availability caveats).

View Topic Context →